Revance Therapeutics (RVNC) Tops Q1 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• DA Davidson Reiterates Buy Rating on Oracle (ORCL) Following Q1 Print
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance